What Has Been The Historical And Current Growth Of The Organoids Market?
The organoids market has seen considerable growth due to a variety of factors.
•The exponential expansion of the organoids market size has been evident in recent years. The rise from $3.98 billion in 2024 to $4.83 billion in 2025, with a compound annual growth rate (CAGR) of 21.3%.
is expected. Factors such as advancements in biomedical research, needs for drug discovery and development, requirements for disease modeling, trends in personalized medicine, and regulatory assistance contribute to this growth in the historic period.
What Is The Forecast For The Organoids Market By 2029?
The organoids market is expected to maintain its strong growth trajectory in upcoming years.
• The market size for organoids is anticipated to experience rapid expansion in the forthcoming years, with a projected growth to $10.82 billion by 2029, and a compound annual growth rate (CAGR) of 22.3%.
This growth during the forecast period can be credited to the escalating incidence of chronic diseases, progress in genome editing methods, an increase in stem cell research, cooperative efforts and partnerships, and efforts in clinical translation. Notable trends for the forecast period include its use in regenerative medicine, the use of in vivo imaging techniques, cooperative development of multi-organoid systems, ethical and legal implications, as well as market commercialization and expansion.
Which Key Drivers Are Propelling The Organoids Market's Growth?
The escalating frequency of chronic and infectious diseases is anticipated to boost the organoid market's progression. Chronic diseases, which require consistent medical attention and last over a year, have been studied widely using organoids for treatment processes since they provide reliable and immediate data about pathogen biology and drug screenings. Consequently, the rise in chronic and infectious diseases will positively impact the organoid market. For illustration, a report from the National Health Service, a public healthcare system in the UK, showed that in June 2024, non-diabetic hyperglycemia or pre-diabetes was diagnosed in 3,615,330 people registered with a GP. This figure represented almost a fifth (18%) increase in contrast to 3,065,825 people in 2023. As such, the organoid market stands to witness growth with the mounting incidence of chronic diseases.
What Are The Key Segments Within The Global Organoids Market?
The organoids market covered in this report is segmented –
1) By Product: Hepatic Organoid, Colorectal Organoid, Intestinal Organoid, Other Organoid
2) By Source: Pluripotent Stem Cells, Organ-Specific Adult Stem Cells
3) By Application: Developmental Biology, Disease Pathology Of Infectious Disease, Regenerative Medicine, Drug Toxicity And Efficacy Testing, Drug Discovery And Personalized Medicine, Other Applications
4) By End-User: Hospitals And Diagnostic Centers, Biotechnology And Pharmaceutical Companies, Other End-Users
Subsegments:
1) By Hepatic Organoid: Hepatic Stem Cell-Derived Organoids, Primary Liver Cell-Derived Organoids, Liver Tumor Organoids
2) By Colorectal Organoid: Colonic Organoids, Rectal Organoids, Colorectal Cancer Organoids
3) By Intestinal Organoid: Small Intestinal Organoids, Enteroid Organoids, Intestinal Stem Cell-Derived Organoids
4) By Other Organoid: Pancreatic Organoids, Brain Organoids, Kidney Organoids, Lung Organoids, Others
Pre-Book The Organoids Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
How Are New Trends Impacting The Size Of The Organoids Market?
The surge in technological innovation is a significant trend emerging in the organoid industry. To maintain their market standing, primary organoid companies are debuting novel organoid technologies. As an illustration, in March 2023, MIMETAS, a Dutch firm specialising in human tissue and illness modelling, introduced a new breed of adult stem cell (ASC)-derived tubular organoids under their OrganoReady product range. Leveraging advanced and groundbreaking technology, this new organoid type is utilised for mechanistic toxicology and medication-induced organ damage research. These organoids are created as perfused 3D tubular structures with entry points on both the apical and basal surfaces, facilitated by the OrganoPlate, their proprietary microfluidic platform.
Who Are the Key Players in the Organoids Market?
Major companies operating in the organoids market include:
• Cellesce Ltd.
• STEMCELL Technologies
• HUB Organoids
• DefiniGEN
• 3Dnamics Inc.
• OcellO B.V.
• Organoid Therapeutics
• PeproTech Inc.
• QGel SA
• Corning Incorporated
• Thermo Fisher Scientific
• Trevigen Inc.
• Path BioAnalytics
• R&D Systems
• Merck KGaA
• 3D BioMatrix Inc.
• 3D Biotek LLC
• AMS Biotechnology (Europe) Limited
• Greiner Bio-One
• 3-D Matrix
• InSphero AG
• Synthego Corporation
• Axol Bioscience Ltd.
• TissUse GmbH
• CytoSMART Technologies BV
• EMD Millipore Corporation
• Epithelix Sàrl
What are the Regional Insights into the Organoids Market?
North America was the largest region in the organoids market in 2024. Asia-Pacific is expected to be the fastest-growing region in the global organoids market size forecast period. The regions covered in the organoids market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
